TXMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TXMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TherapeuticsMD's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.26.
TherapeuticsMD's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.26.
TherapeuticsMD's EPS without NRI for the three months ended in Sep. 2024 was $-0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.24.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
The historical data trend for TherapeuticsMD's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial |
![]() |
![]() |
-36.00 | -33.50 | -21.66 | 12.41 | -0.98 |
TherapeuticsMD Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EPS (Basic) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.32 | -0.06 | -0.06 | -0.09 | -0.05 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
TherapeuticsMD's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-10.278 | - | 0) | / | 10.441 | |
= | -0.98 |
TherapeuticsMD's Basic EPS for the quarter that ended in Sep. 2024 is calculated as
Basic EPS (Q: Sep. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-0.609 | - | 0) | / | 11.532 | |
= | -0.05 |
EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD (NAS:TXMD) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of TherapeuticsMD's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Collins Cooper C. | director | 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354 |
Marlan D Walker | officer: General Counsel | 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431 |
Joseph Ziegler | officer: Principal Financial Officer | 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062 |
Michael C Donegan | officer: CAO and VP of Finance | 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
Brian Bernick | director | 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
Mark A Glickman | officer: Chief Business Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Justin Hunter Roberts | director | C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Tommy G Thompson | director | 7711 CARONDELET, ST. LOUIS MO 63105 |
Karen Ling | director | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Paul Bisaro | director | |
Jules A. Musing | director | 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
David Efraim Rosen | 10 percent owner | 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
From GuruFocus
By Business Wire Business Wire • 05-15-2023
By PRNewswire PRNewswire • 06-30-2022
By PRNewswire PRNewswire • 07-10-2022
By PRNewswire PRNewswire • 07-06-2022
By Business Wire Business Wire • 08-08-2022
By Business Wire • 11-14-2023
By Business Wire • 08-12-2024
By GuruFocus Research GuruFocus Editor • 12-10-2022
By Business Wire Business Wire • 07-13-2022
By PurpleRose PurpleRose • 07-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.